Highly active antiretroviral treatment as prevention of HIV transmission: Review of scientific evidence and update

Current Opinion in HIV and AIDS

Volumn 5, Issue 4, 2010, Pages 298-304

  Granich, Reuben ^a   Crowley, Siobhan ^a   Vitoria, Marco ^a   Smyth, Caoimhe ^a   Kahn, James G ^b   Bennett, Rod ^c   Lo, Ying Ru ^a   Souteyrand, Yves ^a   Williams, Brian ^d  

^a UNAIDS   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Independent Consultant ^*  (United Kingdom)

^d STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Highly active antiretroviral treatment; HIV; Modeling; Prevention; Universal access

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CIRCUMCISION; DISEASE TRANSMISSION; EPIDEMIC; ETHICAL DECISION MAKING; FUNDING; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INVESTMENT; MALE HOMOSEXUAL; MORBIDITY; MORTALITY; PATIENT COUNSELING; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; UNSAFE SEX; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHEMOPREVENTION; HIV INFECTIONS; HUMANS; TIME FACTORS; VIRAL LOAD;

EID: 77953613246     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833a6c32     Document Type: Review

References (77)

1. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871.
2. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector; 2008. http://www.who.int/hiv/pub/towards-universal- access-report-2008.pdf.
3. WHO. Global tuberculosis control: epidemiology, strategy, financing WHO/ HTM/TB/2009.411. Geneva, Switzerland: WHO. http://www.who.int/tb/ publications/global-report/2009/pdf/full-report.pdf; 2009.
4. UNAIDS. Financial resources required to achieve universal access to HIV prevention, treatment, care and support. Geneva, Switzerland: UNAIDS. http://data.unaids.org/pub/Report/2007/20070925-advocacy-grne2- en.pdf; 2007.
5. Global issues: social, political, economic and environmental issues that affect us all http://www.globalissues.org/article/768/global-financial- crisis#The financialcrisisandthedevelopingworld. [Accessed 13 March 2010]
6. United Nations Universal Declaration of Human Rights (article #25). http:// www.un.org/en/documents/udhr/; 1948.
7. UNHCR. HIV/AIDS and human rights: international guidelines. Revised guideline 6: access to prevention, treatment care and support. Geneva, Switzerland: UNHCR. http://whqlibdoc.who.int/publications/2002/ 9291730254.pdf; 2003.
8. UNAIDS. Handbook for legislators on HIV/AIDS, law and human rights. Geneva, Switzerland: UNAIDS. http://www.ipu.org/PDF/publications/aids- en.pdf; 1997.
9. UNHCR. Handbook on HIV and human rights for national human rights institutions. Geneva, Switzerland: UNHCR. http://data.unaids.org/pub/Report/ 2007/jc1367-handbookhiv-en.pdf; 2007.
10. WHO. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. Geneva, Switzerland: WHO. http://www.who.int/hiv/pub/prev-care/OMS-EPP-AFF-en.pdf; 2008.
11. UNAIDS. Practical guidelines for intensifying HIV prevention: towards universal access - UNAIDS/07.07E/JC1274E 2007. Geneva, Switzerland: UNAIDS. http://data.unaids.org/pub/Manual/2007/jc1274-towardsuniversalaccess- en.pdf; 2007.
12. Desrosiers R. Scientific obstacles to an effective HIV vaccine [CROI abstract #91]. Presented at 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008); 2008.
13. Weiss RA. Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol 2008; 152:201-210.
14. Cohen J. HIV/AIDS. The great funding surge. Science 2008; 321:512-519.
15. Karim S. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN035 Trial. In: The 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada. http://www.retroconference. org/2009/Abstracts/36659.htm; 2009.
16. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
17. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536.
18. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
19. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
20. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29:275-283.
21. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101.
22. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92.
23. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
24. Donnell D. ART and risk of heterosexual HIV-1 transmission in HIV-1 serodiscordant African Couples: a multinational prospective study [abstract #136]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, USA; 2010. http://www.retroconference.org/ 2010/Abstracts/39222.htm. [Accessed 13 March 2010]
25. Achievements in public health. Reduction in perinatal transmission of HIV infection - United States, 1985-2005. Morb Mortal Wkly Rep 2006, 55: 592-597.
26. Shapiro R. A randomized trial comparing highly active antiretroviral therapy regimens for virologic efficacy and the prevention of mother-to-child HIV transmissionamong breastfeedingwomen in Botswana. In: 5th IASConference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa. http://www.ias2009.org/pag/PosterExhibition.aspx.
27. Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 338:b1649.
28. Das-Douglas M. Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco [abstract #33]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, USA; 2010. http://www.retroconference.org/2010/Abstracts/ 38232.htm. [Accessed March 13 2010].
29. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885.
30. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
31. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559-567.
32. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335-342.
33. Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717-1725.
34. Ingle S. Pretreatment mortality and probability of starting ART in patients enrolled in the free state ARV Program, South Africa: implications for treatment guidelines [abstract #108]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, USA; 2010. http:// www.retroconference.org/2010/Abstracts/37166.htm. [Accessed March13, 2010
35. Hargrove JW, Humphrey JH. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010, 24:F11-F14.
36. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
37. El-Sadr WM, Grund B, Neuhaus J, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149:289-299.
38. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008, 197:1145-1155
39. Castilla J, Sobrino P, De La Fuente L, et al. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002; 16:1945-1951.
40. Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151:157-166.
41. Jaen A, Esteve A, Miro JM, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 2008; 47:212-220.
42. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697.
43. WHO. Rapid advice, antiretroviral therapy for HIV infection in adults and adolescents. http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf; 2009. [Accessed 14 March 14 2010]
44. NIAID QUESTIONS AND ANSWERS: The CIPRA HT 001 Clinical Trial. http://www3.niaid.nih.gov/news/QA/CIPRA-HT01-qa.htm. [Accessed 13 March 2010]
45. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.
46. Sigel K. HIV infection is an independent risk factor for lung cancer [abstract #30]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, USA; 2010. http://www.retroconference.org/2010/Abstracts/ 38365.htm. [Accessed March 13 2010].
47. Korenromp EL, Williams BG, Schmid GP, Dye C. Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection: a quantitative review. PLoS One 2009; 4:e5950.
48. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
49. Bunnell R, Mermin J, De Cock KM. HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA 2006; 296:855-858.
50. Mohammed I. HIV prevalence and unmet need for HIV testing, care and treatment in Kenya: results of a Nationally Representative Survey. CROI 2009. http://www.retroconference.org/2009/Abstracts/36616.htm.
51. Dunkle KL, Stephenson R, Karita E, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008; 371: 2183-2191.
52. Malamba SS, Mermin JH, Bunnell R, et al. Couples at risk: HIV-1 concordance and discordance among sexual partners receiving voluntary counseling and testing in Uganda. J Acquir Immune Defic Syndr 2005; 39:576-580.
53. Allen S, Tice J, Van de Perre P, et al. Effect of serotesting with counselling on condom use and seroconversion among HIV discordant couples in Africa. BMJ 1992; 304:1605-1609.
54. A company prospers by saving poor people's lives. New York Times; 2 February 2009. http://www.nytimes.com/2009/02/03/health/research/ 03prof.html?-r=1&scp=2&sq=Mikkel+Frandsen&st=nyt.
55. Walensky RP, Wood R, Weinstein MC, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008; 197: 1324-1332.
56. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-493.
57. Walensky R. Test and treat DC, modeling the impact of a comprehensive HIV strategy in the US Capitol [abstract #88]. 5th IAS Conference on HIV Pathogenesis Treatment and Prevention; 19-22 July 2009. http://www. ias2009.org/pag/Abstracts.aspx?AID=3748. [Accessed March 14 2010].
58. Charlebois E. Effect of expanded ART strategies on the MSM HIV epidemic in San Francisco [abstract #996]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, USA; 2010. http://www. retroconference.org/2010/Abstracts/39042.htm. [Accessed 13 March 2010]
59. Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 2009; 373:9-11.
60. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729-735.
61. Scott C. Test and Treat: forecasting the clinical and epidemiological impact of expanded HIV screening and immediate ART in sub-Saharan Africa [abstract #964]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, USA; 2010. http://www.retroconference.org/ 2010/Abstracts/39676.htm. [Accessed 13 March 2010].
62. Smith RJ, Okano JT, Kahn JS, et al. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010; 327:697-701.
63. Vijver Dvd. Potential impact of recent infections, HIV testing and start of antiretroviral drugs at a CD4 of <350 on the HIV epidemic in a rural area in Zambia: a mathematical model [abstract #963]. 17th Conference on Retroviruses andOpportunistic Infections (CROI); San Francisco,USA; 2010. http:// retroconference.org/2010/Abstracts/37500.htm. [Accessed 13 March 2010]
64. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 (Suppl 2):25-36.
65. Kamoto K, Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008; 13 (Suppl 2):83-87.
66. Nguyen HT, Duc NB, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther 2008; 13 (Suppl 2):115-121.
67. Somi GR, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008; 13 (Suppl 2):77-82.
68. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50:98-105.
69. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Organization/ HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther 2008; 13 (Suppl 2):49-57.
70. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 (Suppl 2):1-13.
71. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009; 301:2380-2382.
72. De Cock K. Kevin De Cock: guiding HIV/AIDS policy at WHO. Interview by Priya Shetty. Lancet Infect Dis 2008; 8:98-100.
73. Castel A. Monitoring the impact of expanded HIV testing in the District of Columbia using population-based HIV/AIDS surveillance data [abstract #34]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, USA; 2010. http://www.retroconference.org/2010/Abstracts/ 38192.htm. [Accessed 13 March 2010]
74. Okie S. Fighting HIV, a community at a time. New York Times 26 October 2009. http://www.nytimes.com/2009/10/27/health/27hiv.html. [Accessed 14 March 2010]
75. Montaner J. Association of expanded HAART coverage with a decrease in new HIV diagnoses, particularly among injection drug users in British Columbia, Canada [abstract #88]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, USA; 2010. http://www. retroconference.org/ 2010/Abstracts/39866.htm. [Accessed 13 March 2010]
76. McLaughlin L. A 'test and treat' approach to fighting HIV Boston Globe; 26 February 2010. http://www.boston.com/bostonglobe/editorial-opinion/ oped/articles/2010/02/26/a-test-and-treat-approach-to-fighting-hiv/[Accessed 14 March 2010]
77. De Cock KM, Crowley SP, Lo YR, et al. Preventing HIV transmission with antiretrovirals. Bull World Health Organ 2009; 87:488-1488.